5-Fluorouracil: Mechanisms of action and clinical strategies

被引:3975
作者
Longley, DB [1 ]
Harkin, DP [1 ]
Johnston, PG [1 ]
机构
[1] Queens Univ Belfast, Belfast City Hosp, Dept Oncol, Canc Res Ctr, Belfast BT9 7AB, Antrim, North Ireland
基金
英国医学研究理事会;
关键词
D O I
10.1038/nrc1074
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
5-Fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU, Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.
引用
收藏
页码:330 / 338
页数:9
相关论文
共 109 条
  • [91] Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer
    Seymour, MT
    Slevin, ML
    Kerr, DJ
    Cunningham, D
    James, RD
    Ledermann, JA
    Perren, TJ
    McAdam, WAF
    Harper, PG
    Neoptolemos, JP
    Nicholson, M
    Duffy, AM
    Stephens, RJ
    Stenning, SP
    Taylor, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) : 2280 - 2288
  • [92] The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry
    Sjogren, S
    Inganas, M
    Norberg, T
    Lindgren, A
    Nordgren, H
    Holmberg, L
    Bergh, J
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (3-4) : 173 - 182
  • [93] PURIFICATION AND AMINO-ACID ANALYSIS OF AN ACTIVE-SITE PEPTIDE FROM THYMIDYLATE SYNTHETASE CONTAINING COVALENTLY BOUND 5-FLUORO-2'-DEOXYURIDYLATE AND METHYLENETETRAHYDROFOLATE
    SOMMER, H
    SANTI, DV
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1974, 57 (03) : 689 - 695
  • [94] SPECTOR T, 1995, CANCER RES, V55, P1239
  • [95] FLUOROURACIL AND HIGH-DOSE LEUCOVORIN IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC BREAST-CANCER
    SWAIN, SM
    LIPPMAN, ME
    EGAN, EF
    DRAKE, JC
    STEINBERG, SM
    ALLEGRA, CJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (07) : 890 - 899
  • [96] Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
    Takebayashi, Y
    Akiyama, S
    Akiba, S
    Yamada, K
    Miyadera, K
    Sumizawa, T
    Yamada, Y
    Murata, F
    Aikou, T
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (16): : 1110 - 1117
  • [97] Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells
    Takebe, N
    Zhao, SC
    Ural, AU
    Johnson, MR
    Banerjee, D
    Diasio, RB
    Bertino, JR
    [J]. CANCER GENE THERAPY, 2001, 8 (12) : 966 - 973
  • [98] Takechi T, 1997, CANCER CHEMOTH PHARM, V39, P205
  • [99] Voigt W, 1998, ANTICANCER RES, V18, P3499
  • [100] PHASE-II TRIAL OF FLUOROURACIL AND RECOMBINANT INTERFERON ALFA-2A IN PATIENTS WITH ADVANCED COLORECTAL-CARCINOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY
    WADLER, S
    LEMBERSKY, B
    ATKINS, M
    KIRKWOOD, J
    PETRELLI, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (10) : 1806 - 1810